TNGX

Tango Therapeutics Inc. (TNGX) | Rumor.io

Tango Therapeutics

TNGX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,160

Bullish sentiment (50-day avg)78%

Price to earnings ratio-28

Market capitalization4.1B

Earnings per share-0.82

Dividend yield (TTM)—

Revenue (annual)62.4M

Net income (annual)-101.6M

Social

What share of all stock conversation is about TNGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Jul 15

JPMorgan initiated coverage of Tango Therapeutics with an Overweight rating and $46 price target, citing the company's lead in pancreatic ductal adenocarcinoma and potential lung cancer treatment.
The analyst highlights impressive results from Tango's combo trials with RAS inhibitors, driving growth upside.
With a $46 price target, Tango's stock is expected to increase by approximately 55% from its current price.

Generated by AI

Sentiment

Of the messages about TNGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	66.67% -33.33	75.4% -0.72	86.58% +2.95
Bearish	0%	33.33% +33.33	24.6% +0.72	13.42% -2.95

Bullish· Jun 9

Multiple analysts have raised their price targets for $TNGX, with some increasing their targets by as much as $14.
$TNGX has reported positive Phase 1/2 clinical trial data, showing strong survival improvement and "unprecedented" results according to analysts.
The stock has surged 52.97% on high volume, with institutional interest and relative strength indicators suggesting continued momentum.

Bearish· Jun 8

The market is expected to be pressured by AI, potentially weighing on $TNGX.
$TNGX has a high short interest of 45%, which may contribute to its downward trend.
A large 500m offering is planned, which could lead to a significant increase in supply and further downward pressure on the stock.

Generated by AI

Topics

Of the messages about TNGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	82.43%
Technical Analysis	0%	0%	0%	8.78%
Analysts	0%	0%	0%	6.26%
Earnings	0%	0%	0%	0.5%
Controversies	0%	0%	0%	0.11%
Macro	0%	0%	0%	1.92%

Announcements· Jun 8

Tango Therapeutics ($TNGX) announced positive initial Phase 1/2 data for its PRMT5 inhibitor, vopimetostat, combined with Revolution Medicines' RAS(ON) inhibitors, showing a 92% objective response rate in pancreatic cancer.
The vopimetostat-daraxonrasib cohort also demonstrated a 100% disease control rate and a 90% six-month progression-free survival rate in pancreatic cancer patients.
$TNGX stock surged 45% on the news, with the company's market value increasing significantly due to the promising results in the treatment of pancreatic cancer.

Technical Analysis· Aug 9

$TNGX has formed key support at 7.7 - 8 and may break $10 if it holds this support.
The stock is showing signs of reconsolidation around $8.20, with a consistent bottom bounce serving as a support level.
A breakout of $TNGX's resistance at $8.91 could send the stock parabolic, with huge momentum back in small caps.

Generated by AI

Community

Of the messages about TNGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.81%	58.29%	45.43%
Newcomers	0%	3.19%	41.71%	54.57%

Regulars· Jun 9

$TNGX's stock price target has been raised to $69 by Leerink, to $36 by Mizuho, and to $35 by B. Riley, with B. Riley maintaining a buy rating.
The company's P1 results for Vopimetostat in Non-Small-Cell Lung Cancer and Glioblastoma are expected to be presented in 2H26, and P1 results for Daraxonrasib in Pancreatic Ductal Carcinoma and Non-Small-Cell Lung Cancer were presented on 2026-06-08.
The company's results highlighted that RAS and MTAP double mutant lung cancer cases are as many as all ALK cases, and the combo therapy is expected to stay years, with $GSK's involvement and pricing implications being a major topic of discussion.

Newcomers· Jun 27

The newcomer is focusing on the potential for a price pullback in Tango Therapeutics, Inc. ($TNGX) stock.
There is speculation about the company's name and its potential impact on the stock's performance.
The newcomer is taking a cautious approach to the stock, suggesting it may drop in value over the next few days.

Generated by AI

News

Tango Therapeutics principal accounting officer sells $198k in stock

5d agoInvesting.com

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

19d agofinance.yahoo.com

Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path

20d agoInvesting.com

Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey

Tango Therapeutics stock reaction and recent performance Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company’s recent performance. Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about...

26d agoYahoo Finance

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for th

26d agoYahoo Finance

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be a

29d agoYahoo Finance

Also Discussed

Investors talking about TNGX also mention

#	Name	Attention
1	Relay Therapeutics Inc.RLAY	0%new
2	Arcus Biosciences, Inc.RCUS	0%new
3	Cullinan Therapeutics Inc.CGEM	0%new
4	Kulicke & Soffa Industries, Inc.KLIC	0%0
5	Revolution Medicines, Inc.RVMD	0.01%-0.01
6	Nurix Therapeutics, Inc.NRIX	0%new
7	IDEAYA Biosciences Inc.IDYA	0%-0.01
8	Kymera Therapeutics Inc.KYMR	0%0
9	Erasca Inc.ERAS	0%0
10	TTEC Holdings, Inc.TTEC	0%0

Tango Therapeutics Inc.

Healthcare
Biotechnology

Tango Therapeutics Inc. is a biotechnology company focused on discovering and developing precision oncology therapies. The company applies synthetic lethality and target discovery approaches to identify cancer dependencies that can be addressed with medicines designed for specific tumor types. Its current pipeline centers on programs in oncology, including PRMT5 inhibitor candidates aimed at cancers such as pancreatic, lung, and brain tumors, along with research efforts tied to tumor suppressor gene loss and other genetically defined patient populations. Tango Therapeutics Inc. operates in the clinical-stage drug development segment, where its work contributes to the broader precision medicine market by advancing targeted approaches intended to improve cancer treatment specificity. The company is headquartered in Boston, Massachusetts, and is positioned within the life sciences sector as a developer of innovative therapeutic candidates for patients with high unmet medical need.

Website

Location

201 Brookline Avenue

Boston, MA, 02215

United States

Social

What share of all stock conversation is about TNGX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Jul 15

JPMorgan initiated coverage of Tango Therapeutics with an Overweight rating and $46 price target, citing the company's lead in pancreatic ductal adenocarcinoma and potential lung cancer treatment.
The analyst highlights impressive results from Tango's combo trials with RAS inhibitors, driving growth upside.
With a $46 price target, Tango's stock is expected to increase by approximately 55% from its current price.

Generated by AI

Sentiment

Of the messages about TNGX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	66.67% -33.33	75.4% -0.72	86.58% +2.95
Bearish	0%	33.33% +33.33	24.6% +0.72	13.42% -2.95

Bullish· Jun 9

Multiple analysts have raised their price targets for $TNGX, with some increasing their targets by as much as $14.
$TNGX has reported positive Phase 1/2 clinical trial data, showing strong survival improvement and "unprecedented" results according to analysts.
The stock has surged 52.97% on high volume, with institutional interest and relative strength indicators suggesting continued momentum.

Bearish· Jun 8

The market is expected to be pressured by AI, potentially weighing on $TNGX.
$TNGX has a high short interest of 45%, which may contribute to its downward trend.
A large 500m offering is planned, which could lead to a significant increase in supply and further downward pressure on the stock.

Generated by AI

Topics

Of the messages about TNGX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	82.43%
Technical Analysis	0%	0%	0%	8.78%
Analysts	0%	0%	0%	6.26%
Earnings	0%	0%	0%	0.5%
Controversies	0%	0%	0%	0.11%
Macro	0%	0%	0%	1.92%

Announcements· Jun 8

Tango Therapeutics ($TNGX) announced positive initial Phase 1/2 data for its PRMT5 inhibitor, vopimetostat, combined with Revolution Medicines' RAS(ON) inhibitors, showing a 92% objective response rate in pancreatic cancer.
The vopimetostat-daraxonrasib cohort also demonstrated a 100% disease control rate and a 90% six-month progression-free survival rate in pancreatic cancer patients.
$TNGX stock surged 45% on the news, with the company's market value increasing significantly due to the promising results in the treatment of pancreatic cancer.

Technical Analysis· Aug 9

$TNGX has formed key support at 7.7 - 8 and may break $10 if it holds this support.
The stock is showing signs of reconsolidation around $8.20, with a consistent bottom bounce serving as a support level.
A breakout of $TNGX's resistance at $8.91 could send the stock parabolic, with huge momentum back in small caps.

Generated by AI

Community

Of the messages about TNGX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.81%	58.29%	45.43%
Newcomers	0%	3.19%	41.71%	54.57%

Regulars· Jun 9

$TNGX's stock price target has been raised to $69 by Leerink, to $36 by Mizuho, and to $35 by B. Riley, with B. Riley maintaining a buy rating.
The company's P1 results for Vopimetostat in Non-Small-Cell Lung Cancer and Glioblastoma are expected to be presented in 2H26, and P1 results for Daraxonrasib in Pancreatic Ductal Carcinoma and Non-Small-Cell Lung Cancer were presented on 2026-06-08.
The company's results highlighted that RAS and MTAP double mutant lung cancer cases are as many as all ALK cases, and the combo therapy is expected to stay years, with $GSK's involvement and pricing implications being a major topic of discussion.

Newcomers· Jun 27

The newcomer is focusing on the potential for a price pullback in Tango Therapeutics, Inc. ($TNGX) stock.
There is speculation about the company's name and its potential impact on the stock's performance.
The newcomer is taking a cautious approach to the stock, suggesting it may drop in value over the next few days.

Generated by AI

Tango Therapeutics

Social

Jul 15

Bullish· Jun 9

Bearish· Jun 8

Announcements· Jun 8

Technical Analysis· Aug 9

Regulars· Jun 9

Newcomers· Jun 27

Tango Therapeutics principal accounting officer sells $198k in stock

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path

Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Also Discussed

Tango Therapeutics Inc.

Company Information

Location

Tango Therapeutics principal accounting officer sells $198k in stock

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path

Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Also Discussed

Social

Jul 15

Bullish· Jun 9

Bearish· Jun 8

Announcements· Jun 8

Technical Analysis· Aug 9

Regulars· Jun 9

Newcomers· Jun 27